03/01/2022 Provider Alert: UPDATE – COVID-19 Therapies

stethoscope sitting on laptop keyboard

Requested Actions

  • Be aware, providers should contact and re-dose patients who previously received the 150mg Evushield dose (see below)
  • Be Aware, supply of COVID-19 therapeutics is not currently limited in Whatcom County. While COVID-19 case rates are decreasing in Whatcom County, some patients may benefit from therapeutics. Decision to prescribe should be based on clinical criteria and patient interest.
  • Be aware, CDC updated its list of underlying medical conditions associated with higher risk of severe outcomes from COVID-19 to include primary immunodeficiency and physical inactivity. The list is not exhaustive. Do not use it to exclude people from recommended preventive measures, like booster doses or needed therapies.


COVID-19 Therapeutics Availability

  • Whatcom County now has a good supply of COVID-19 therapeutics. Department of Health and Human Services (HHS) allocates monoclonal antibodies and oral antivirals to each state and the WA DOH distributes doses to enrolled medical providers and pharmacies. All therapies must be dispensed by prescription.


  • Oral antivirals: Numerous pharmacies throughout Whatcom County have a regular supply of Molnupiravir and several sites have Paxlovid.
    • See the HHS COVID-19 therapeutics locatorfor locations and availability.
    • Oral antivirals must be taken ASAP within 5 days of symptom onset; Rx must include date of symptom onset or “do not take after [date]” to ensure 5-day window.


  • Monoclonal antibodies: There are currently no supply constraints for Sotrovimab, the mAb effective for treatment of omicron.
    • Evusheld: Pre-exposure prophylaxis, primarily for immunocompromised or those who cannot be vaccinated.
    • See the HHS COVID-19 therapeutics locator for locations and availability.
    • On Feb. 24, Food and Drug Administration (FDA) revised its Evusheld emergency use authorization (EUA) (tixagevimab co-packaged with cilgavimab). When used for COVID-19 pre-exposure prophylaxis, the new initial dose is 300 mg tixagevimab and 300 mg cilgavimab. Recent data shows Evusheld may be less active against some Omicron subvariants. Contact patients who received the previous initial dose (150 mg tixagevimab and 150 mg cilgavimab) and ask them to return for an additional 150 mg tixagevimab and 150 mg cilgavimab.
    • See updated Evusheld EUA for more information.

 Prescribing Information and Tools

  • Therapeutics Decision Aid (2-page algorithm, updated 2/24/22):


  • Side-by-Side Overview of Therapies (9-page comparison chart):


Additional information

COVID-19 at-home antigen tests

Contacting the Health Department

360-778-6100    Main Call Line – available M-F 8:30am to 4:30pm

360-715-2588    Afterhours Answering Service – available after 4:30pm and weekends

360-778-6150    Communicable Disease Report Line – 24 hours a day 7 days a week

360-778-6103    Confidential Communicable Disease Fax – 24 hours a day 7 days a week

1500 N State Street, Bellingham WA 98225